RT Journal Article
T1 Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure.
A1 Rúa-Figueroa, Iñigo
A1 Rúa-Figueroa, David
A1 Pérez-Veiga, Natalia
A1 Anzola, Ana M
A1 Galindo-Izquierdo, María
A1 Calvo-Alén, Jaime
A1 Fernández-Nebro, Antonio
A1 Sangüesa, Clara
A1 Menor-Almagro, Raúl
A1 Tomero, Eva
A1 Del Val, Natividad
A1 Uriarte-Isazelaya, Esther
A1 Blanco, Ricardo
A1 Andreu, José L
A1 Boteanu, Alina
A1 Narváez, Javier
A1 Cobo, Tatiana
A1 Bohórquez, Cristina
A1 Montilla, Carlos
A1 Salas, Esteban
A1 Toyos, Francisco J
A1 Bernal, José A
A1 Salgado, Eva
A1 Freire, Mercedes
A1 Mas, Antonio J
A1 Expósito, Lorena
A1 Hernández-Beriain, José A
A1 Ibarguengoitia, Oihane
A1 Velloso-Feijoo, María L
A1 Lozano-Rivas, Nuria
A1 Bonilla, Gemma
A1 Moreno, Mireia
A1 Jiménez, Inmaculada
A1 Quevedo-Vila, Víctor
A1 Pecondón, Angela
A1 Aurrecoechea, Elena
A1 Valls, Elia
A1 Mouriño, Coral
A1 Vázquez-Rodríguez, Tomás
A1 Pego-Reigosa, José M
K1 Antimalarials
K1 Chronic heart failure
K1 Systemic lupus erythematosus
AB Factors associated with chronic heart failure (CHF) in patients with systemic lupus erythematosus (SLE) have received little attention. Recent data on the use of hydroxychloroquine in the treatment of SARS-CoV-2 infection have cast doubt on its cardiac safety. The factors associated with CHF, including therapy with antimalarials, were analyzed in a large multicenter SLE cohort. Cross-sectional study including all patients with SLE (ACR-1997 criteria) included in the Spanish Society of Rheumatology Lupus Register (RELESSER), based on historically gathered data. Patients with CHF prior to diagnosis of SLE were excluded. A multivariable analysis exploring factors associated with CHF was conducted. The study population comprised 117 patients with SLE (ACR-97 criteria) and CHF and 3,506 SLE controls. Ninety percent were women. Patients with CHF were older and presented greater SLE severity, organ damage, and mortality than those without CHF. The multivariable model revealed the factors associated with CHF to be ischemic heart disease (7.96 [4.01-15.48], p  Patients with SLE and CHF experience more severe SLE. Treatment with antimalarials appears to confer a cardioprotective effect.
YR 2022
FD 2022-01-02
LK http://hdl.handle.net/10668/22513
UL http://hdl.handle.net/10668/22513
LA en
DS RISalud
RD Apr 18, 2025